Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Infliximab (SB2, EU Sourced Remicade and US Sourced Remicade) in Healthy Subjects

Next Previous
Trial Profile

A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Infliximab (SB2, EU Sourced Remicade and US Sourced Remicade) in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacokinetics; Registrational
  • Sponsors Samsung Bioepis

Most Recent Events

  • 01 Nov 2017 Results assessing PK profiles of SB2 in healthy subjects and patients with rheumatoid arthritis using patient data from NCT01936181 and NCT01922336 trials presented at the 25th United European Gastroenterology Week
  • 30 May 2016 According to a Biogen media release, The European Commission (EC) has granted marketing authorization in the European Union (EU) for FLIXABI (Infliximab Biosimilar) based on the data from this and a phase III trial (see profile 235251).
  • 23 May 2016 According to Merck media release, Biologics License Application (BLA) of SB2 (infliximab) by Samsung Bioepis has been accepted for review by the U.S. Food and Drug Administration (FDA).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top